Grown Rogue International (GRIN) Investor presentation summary

Transaction overview

• Planned acquisition of PharmaCann's New York license and assets, including four dispensaries and a 100,000+ sq ft cultivation and manufacturing campus.

• 51/49 ownership structure with Grown Rogue retaining majority equity and a minority partner providing $10M preferred equity and up to $5M in drawable term loan.

• Estimated $12M in project requirements with a $3M capital cushion, minimizing balance sheet risk.

• Interim agreements allow operational control and funding prior to regulatory approval and closing.

• Definitive purchase agreements and regulatory approval required for ownership transfer.

Market opportunity and strategy

• New York cannabis market is growing, with July 2026 sales at $163M, up 5.9% YoY.

• Market characterized by fragmented retail and limited high-quality indoor flower supply.

• Only about six large-scale indoor flower facilities exist, creating a premium flower gap.

• New York's discerning consumer base offers brand-building potential for differentiated flower products.

• Pricing for flower in New York is comparable to New Jersey, supporting premium positioning.

Operating platform and plan

• Hamptonburgh facility includes 24K sq ft indoor and 16K sq ft greenhouse canopy, with significant manufacturing and extraction capabilities.

• Four Verilife dispensaries generate $1.7–$2.0M monthly sales, historically skewed toward medical and first-party products.

• Production ramp expected to take six to nine months, with some transition disruption anticipated.

• Cost reset plan targets $20M in annual savings through lease adjustments and operational efficiencies.

• Local team retention and flower-forward execution are central to the operating strategy.